You are here: Industry Insights > J&J

News List

Jury smacks J&J with $325M talc verdict after a series of other wins fiercepharma
June 05, 2019
After recent wins and losses, Johnson & Johnson capped the month of May with a major setback in its talc litigation.
J&J to invest €100 million into Limerick manufacturing facilities creating 100 new jobs pharmafile
May 17, 2019
Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care manufacturing facilities in Limerick. The expansion is expected to see the creation of 100 new jobs.
ICER’s Evidence Report Finds Esketamine May Benefit Patients with Treatment-Resistant Depression but Exceeds Cost-Effectiveness Thresholds firstwordpharma
May 10, 2019
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of esketamine (Spravato™, Janssen) ...
FDA speeds Bayer's J&J-Pfizer showdown with darolutamide 'priority' fiercepharma
May 06, 2019
Johnson & Johnson and the Pfizer-Astellas team have grown accustomed to a two-horse race in prostate cancer. But it may not be long before a third joins them.
J&J's quest to detect lung cancer before it emerges fiercebiotech
April 28, 2019
Smoking causes injuries in the respiratory tract that can evolve into lung cancer. Researchers from Johnson & Johnson Innovation and Boston University wondered whether it might be possible to prevent lung lesions from becoming cancerous ...
J&J, under 'accelerating' generic and biosim attack…… fiercepharma
April 18, 2019
Johnson & Johnson's pharma business has been beating the market for years now, but that's about to change. A wave of ……
On the heels of victory in New Jersey, J&J scores another talc win in California fiercepharma
April 09, 2019
After a recent talc trial loss in California and a win in New Jersey, J&J has prevailed in the latest case to reach a verdict.
J&J completes acquisition of Auris Health biospectrumasia
April 04, 2019
Johnson & Johnson announced that its subsidiary Ethicon has completed the acquisition of Auris Health for approximately $3.4 billion in cash.
J&J submits sNDA for Invokana after premature end to clinical trial pharmatimes
April 02, 2019
Johnson & Johnson’s Janssen has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for a new indication for Invokana (canagliflozin).
J&J launches industry-first TV ad with drug list price fiercepharma
April 02, 2019
Johnson & Johnson’s anticoagulant Xarelto has picked up an industry first. On Friday, it became the subject of the first-ever TV drug ad with a list price included.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page